Saint Luke's Research

Advancing patient care and population health through innovative research

Research has been the heart of Saint Luke’s for more than 135 years. Saint Luke’s Research strives to continuously improve the quality and value of health care as a national leader in clinical, translational, and outcomes research. Our mission is to advance the prevention and treatment of disease, helping patients live healthier and longer lives.

Saint Luke’s Office of Research Services works with Saint Luke’s affiliated researchers across the health system to make research more effective by assisting with planning, implementation, and logistics. Research Services offers the support infrastructure to further strengthen Saint Luke’s role as a national leader in research.

 

OFFICE OF RESEARCH SERVICES

Provides a centralized and comprehensive infrastructure for research at Saint Luke’s.

Learn more

RESEARCH PROGRAMS

Saint Luke’s physicians within our institutes participate in industry-leading research.

CLINICAL TRIALS

Research studies at Saint Luke’s need participants of all ages and backgrounds.

Browse current studies

Support advanced research

Donor generosity enables our health system to investigate, identify, and provide the safest, innovative technologies and state-of-the-art treatments possible to patients now and for generations to come. Create a healthier tomorrow by investing in clinical research today.

News

May. 31, 2024

KSHB: Are Weight-Loss Drugs the Future of Medicine? Here's What KC-Area Experts Had to Say
KSHB talked to Dr. Mikhail Kosiborod about the significant impact of new weight-loss drugs for those who need it most.
May. 30, 2024

U.S. News & World Report: Mummies Study Finds Heart Disease Plagued the Ancients, Too
U.S. News & World Report shares results of a new study finding heart disease has plagued humanity for centuries.
May. 30, 2024

FOX4: Ancient Mummies Focus of Heart Research Led by Saint Luke's Mid America Heart Institute
FOX4 talked to Dr. Randall Thompson about the decade-long study of ancient mummies.
Apr. 8, 2024

MEDIA COVERAGE: Obesity Medication Proves Effective in Treating Patients with Obesity-Related Heart Failure and Type 2 Diabetes
A new study led by Dr. Mikhail Kosiborod found patients with obesity-related heart failure and type 2 diabetes had significant improvement in symptoms and physical limitations when taking semaglutide.
Apr. 8, 2024

CNN: Weight-Loss Drug Wegovy Offers Benefits for People with Diabetes and Common Form of Heart Failure, Study Finds
The popular weight loss drug Wegovy seems to provide more health benefits for people who have diabetes and a common kind of heart failure than just helping take off the pounds, according to the results from the STEP HFpEF DM trial.
Mar. 20, 2024

Higher Omega-3 Levels Associated with Improved Life Expectancy
New study led by Saint Luke’s Mid America Heart Institute cardiologists reveals lower risk of all-cause and cause-specific mortality associated with higher docosahexaenoic acid (DHA) blood levels
Oct. 27, 2023

TCDMD: TRILUMINATE Deep Dive Clarifies 'Meaningful' Quality of Life Gains with Tricuspid TEER

Dr. Suzanne Arnold presented findings from the pivotal TRILUMINATE trial.
Feb. 15, 2024

TCTMD: Study IDs Patients Most Likely to Quit Smoking After ASCVD Event
TCTMD talked to Dr. Vittal Hejjaji about a large registry study that looked at when patients quit smoking following an atherosclerotic cardiovascular disease event.
Dec. 20, 2023

KMBC: KC-Led Clinical Trial on Popular Weight-Loss Drug Named Scientific 'Breakthrough of the Year'
The study revealed the popular weight loss drug semaglutide — commonly known as Ozempic and Wegovy — is highly effective at treating heart failure in patients with obesity.
Dec. 20, 2023

Kansas City Business Journal: Kansas City-Led Clinical Trial on Popular Weight-Loss Drug is Honored as a 'Breakthrough of the Year'
A groundbreaking study, led by Mikhail Kosiborod, MD, vice president of research at Saint Luke's Health System, has been named the scientific breakthrough of the year by Science Magazine.
Nov. 16, 2023

Cardiovascular Business: TAVR Linked to Favorable Outcomes for Asymptomatic and Minimally Symptomatic Patients—But is it Necessary?
TAVR in asymptomatic and minimally symptomatic patients is associated with a high survival rate, but relatively minor improvements, according to new research.
Nov. 2, 2023

Leader's Edge: Splurging on Surgeries
Dr. John Spertus shares the implications of the ISCHEMIA trial on health care spending.
Oct. 27, 2023

TCDMD: TRILUMINATE Deep Dive Clarifies 'Meaningful' Quality of Life Gains with Tricuspid TEER

Dr. Suzanne Arnold presented findings from the pivotal TRILUMINATE trial.
Oct. 27, 2023

Medpage Today: Tricuspid Clip Might Work for More Patients Than Thought
Tricuspid transcatheter edge-to-edge repair performed better than anticipated in patients expected to have only a modest benefit due to more complex anatomy, the TRILUMINATE trial showed.
Oct. 25, 2023

New York Times: Even Short Runs Have Major Health Benefits
Dr. James O'Keefe explains why even short runs have major health benefits.
Oct. 13, 2023

Cardiovascular Business: Flurpiridaz Will Have a Major Impact on Cardiac PET and Nuclear Imaging
Dr. Timothy Bateman spoke with Cardiovascular Business about his group's findings and what it is like to work with flurpiridaz.